Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZYDUS LIFESCIENCES vs GSK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZYDUS LIFESCIENCES GSK PHARMA ZYDUS LIFESCIENCES/
GSK PHARMA
 
P/E (TTM) x 34.2 62.2 55.0% View Chart
P/BV x 5.8 18.9 30.6% View Chart
Dividend Yield % 0.6 1.6 36.2%  

Financials

 ZYDUS LIFESCIENCES   GSK PHARMA
EQUITY SHARE DATA
    ZYDUS LIFESCIENCES
Mar-23
GSK PHARMA
Mar-23
ZYDUS LIFESCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4951,684 29.4%   
Low Rs3191,231 26.0%   
Sales per share (Unadj.) Rs170.3191.9 88.7%  
Earnings per share (Unadj.) Rs19.835.9 55.1%  
Cash flow per share (Unadj.) Rs26.939.8 67.7%  
Dividends per share (Unadj.) Rs6.0032.00 18.8%  
Avg Dividend yield %1.52.2 67.1%  
Book value per share (Unadj.) Rs173.0102.9 168.2%  
Shares outstanding (eoy) m1,012.20169.41 597.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.47.6 31.5%   
Avg P/E ratio x20.640.6 50.7%  
P/CF ratio (eoy) x15.136.7 41.3%  
Price / Book Value ratio x2.414.2 16.6%  
Dividend payout %30.389.2 34.0%   
Avg Mkt Cap Rs m412,144246,858 167.0%   
No. of employees `000NANA-   
Total wages/salary Rs m24,5645,950 412.9%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m172,37432,517 530.1%  
Other income Rs m4,7461,007 471.5%   
Total revenues Rs m177,12033,524 528.3%   
Gross profit Rs m29,6778,033 369.4%  
Depreciation Rs m7,227658 1,098.9%   
Interest Rs m1,29918 7,168.9%   
Profit before tax Rs m25,8978,364 309.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,8782,288 257.0%   
Profit after tax Rs m20,0196,076 329.5%  
Gross profit margin %17.224.7 69.7%  
Effective tax rate %22.727.4 83.0%   
Net profit margin %11.618.7 62.1%  
BALANCE SHEET DATA
Current assets Rs m100,08224,943 401.2%   
Current liabilities Rs m55,26713,264 416.7%   
Net working cap to sales %26.035.9 72.4%  
Current ratio x1.81.9 96.3%  
Inventory Days Days5097 51.7%  
Debtors Days Days94216 43.3%  
Net fixed assets Rs m144,7766,988 2,071.9%   
Share capital Rs m1,0121,694 59.7%   
"Free" reserves Rs m174,14615,735 1,106.7%   
Net worth Rs m175,15817,430 1,005.0%   
Long term debt Rs m00-   
Total assets Rs m244,94031,930 767.1%  
Interest coverage x20.9462.6 4.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.0 69.1%   
Return on assets %8.719.1 45.6%  
Return on equity %11.434.9 32.8%  
Return on capital %15.548.1 32.3%  
Exports to sales %39.20-   
Imports to sales %11.948.1 24.8%   
Exports (fob) Rs m67,577NA-   
Imports (cif) Rs m20,54415,630 131.4%   
Fx inflow Rs m67,5771,622 4,167.1%   
Fx outflow Rs m20,54415,630 131.4%   
Net fx Rs m47,033-14,008 -335.8%   
CASH FLOW
From Operations Rs m26,8884,842 555.3%  
From Investments Rs m11,7128,079 145.0%  
From Financial Activity Rs m-44,004-15,433 285.1%  
Net Cashflow Rs m-5,338-2,512 212.5%  

Share Holding

Indian Promoters % 75.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 18.0 11.6 155.7%  
FIIs % 5.0 2.9 170.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 25.0 100.1%  
Shareholders   306,495 114,663 267.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZYDUS LIFESCIENCES With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    MANKIND PHARMA    


More on Cadila Healthcare vs GSK Pharma

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Cadila Healthcare vs GSK Pharma Share Price Performance

Period Cadila Healthcare GSK Pharma S&P BSE HEALTHCARE
1-Day 0.57% 3.26% 1.18%
1-Month 7.77% -9.77% -0.75%
1-Year 107.52% 52.63% 61.82%
3-Year CAGR 32.30% 10.89% 18.16%
5-Year CAGR 24.52% 8.44% 19.79%

* Compound Annual Growth Rate

Here are more details on the Cadila Healthcare share price and the GSK Pharma share price.

Moving on to shareholding structures...

The promoters of Cadila Healthcare hold a 75.0% stake in the company. In case of GSK Pharma the stake stands at 75.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Cadila Healthcare and the shareholding pattern of GSK Pharma.

Finally, a word on dividends...

In the most recent financial year, Cadila Healthcare paid a dividend of Rs 6.0 per share. This amounted to a Dividend Payout ratio of 30.3%.

GSK Pharma paid Rs 32.0, and its dividend payout ratio stood at 89.2%.

You may visit here to review the dividend history of Cadila Healthcare, and the dividend history of GSK Pharma.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.